A phase III national, multicentre, randomized open-label study with Lenalidomide/Dexamethasone versus Lenalidomide/Dexamethasone and autologous stem cell transplantation followed by Lenalidomide maintenance therapy for patients with relapsed Multiple Myeloma
Phase of Trial: Phase III
Latest Information Update: 05 Jul 2017
At a glance
- Drugs Lenalidomide (Primary) ; Ciprofloxacin; Dexamethasone; Low molecular weight heparin; Melphalan; Zoledronic acid
- Indications Multiple myeloma
- Focus Registrational; Therapeutic Use
- Acronyms ReLApsE
- 03 Jul 2017 Status changed from recruiting to completed.
- 06 Oct 2016 Planned End Date changed from 26 Sep 2015 to 30 Jun 2017.
- 06 Oct 2016 Status changed from completed to recruiting.